This company listing is no longer active
ALONC Stock Overview
Oncodesign Société Anonyme, a biopharmaceutical company, conducts research and development work on new therapeutic and diagnostic tools with pharmaceutical firms, biotech companies, public research institutions, and investment groups. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Oncodesign Société Anonyme Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €14.42 |
| 52 Week High | €14.64 |
| 52 Week Low | €7.83 |
| Beta | 1.33 |
| 11 Month Change | 0.14% |
| 3 Month Change | 1.55% |
| 1 Year Change | 57.25% |
| 33 Year Change | 63.12% |
| 5 Year Change | 25.39% |
| Change since IPO | 113.63% |
Recent News & Updates
Shareholder Returns
| ALONC | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | 0% | -2.9% | -2.3% |
| 1Y | 57.3% | -23.3% | -3.9% |
Return vs Industry: ALONC exceeded the French Biotechs industry which returned -61% over the past year.
Return vs Market: ALONC exceeded the French Market which returned -9.6% over the past year.
Price Volatility
| ALONC volatility | |
|---|---|
| ALONC Average Weekly Movement | 1.7% |
| Biotechs Industry Average Movement | 6.9% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in FR Market | 9.4% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: ALONC has not had significant price volatility in the past 3 months.
Volatility Over Time: ALONC's weekly volatility has decreased from 8% to 2% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 236 | Philippe Genne | www.oncodesign.com |
Oncodesign Société Anonyme, a biopharmaceutical company, conducts research and development work on new therapeutic and diagnostic tools with pharmaceutical firms, biotech companies, public research institutions, and investment groups. It offers integrated drug discovery services; in vitro and in vivo pharmacology services; services for studying the metabolism and pharmacokinetics of drug candidates; and translational biomarkers, biodecontamination/biosafety, and biobanking services. The company also engages in the analysis of new chemical and biological entities, and membrane proteins; and immuno analysis and monitoring, and microbiological monitoring activities.
Oncodesign Société Anonyme Fundamentals Summary
| ALONC fundamental statistics | |
|---|---|
| Market cap | €99.44m |
| Earnings (TTM) | -€6.19m |
| Revenue (TTM) | €32.67m |
3.0x
P/S Ratio-16.1x
P/E RatioIs ALONC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALONC income statement (TTM) | |
|---|---|
| Revenue | €32.67m |
| Cost of Revenue | €17.60m |
| Gross Profit | €15.07m |
| Other Expenses | €21.26m |
| Earnings | -€6.19m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.90 |
| Gross Margin | 46.14% |
| Net Profit Margin | -18.94% |
| Debt/Equity Ratio | 232.0% |
How did ALONC perform over the long term?
See historical performance and comparison